{
    "name": "cannabidiol",
    "comment": "Rx",
    "other_names": [
        "Epidiolex"
    ],
    "classes": [
        "Anticonvulsants",
        "Cannabinoids"
    ],
    "source": "https://reference.medscape.com/drug/epidiolex-cannabidiol-1000225",
    "pregnancy": {
        "common": [
            "There are no available data regarding use in pregnant women",
            "Based on animal data, may cause fetal harm"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration of cannabidiol to pregnant animals produced evidence of developmental toxicity (increased embryofetal mortality in rats and decreased fetal body weights in rabbits decreased growth, delayed sexual maturation, long-term neurobehavioral changes, and adverse effects on the reproductive system in rat offspring) at maternal plasma exposures similar to (rabbit) or greater than (rat) that in humans at therapeutic doses"
                ]
            },
            {
                "type": "AED pregnancy registry",
                "description": [
                    "There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs during pregnancy",
                    "Encourage women who are taking cannabidiol during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll-free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of cannabidiol or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to cannabidiol or any of the product ingredients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Can cause somnolence and sedation that is dose-related; clobazam and other CNS depressants, including alcohol, may potentiate this adverse effect; monitor for somnolence and sedation and advise patients not to drive or operate machinery until they have gained sufficient experience on drug to gauge whether it adversely affects their ability to safely drive or operate machinery",
                "Antiepileptic drugs (AEDs), including cannabidiol, increase risk of suicidal thoughts or behavior in patients taking these drugs for any indication; patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior",
                "May cause hypersensitivity reactions (eg, pruritus, erythema, angioedema)",
                "As with other AEDs, cannabidiol should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus; if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered ",
                "Therapy can cause weight loss, which may be dose-related",
                "A decrease in hemoglobin and hematocrit reported with no effect on red blood indices",
                "Elevation of serum creatinine reported within 2 weeks of initiating therapy that was reversible in healthy adults; mechanism not determined"
            ],
            "specific": [
                {
                    "type": "Hepatocellular injury",
                    "description": [
                        "Dose-related liver transaminases (ALT and/or AST) elevations reported, typically within the first 2 months of treatment",
                        "Majority of ALT elevations occurred when coadministered with valproate and, to a lesser extent, with clobazam",
                        "In 25 mg/kg/day treated patients with TSC, the incidence of ALT elevations greater than 3 times the ULN was 20% in patients taking both concomitant valproate and clobazam, 25% in patients taking concomitant valproate (without clobazam), 0% in patients taking concomitant clobazam (without valproate), and 6% in patients taking neither drug; consider discontinuation or dose adjustment of valproate or clobazam if liver enzyme elevations occur",
                        "Obtain serum transaminases before initiating and regularly afterward; consider more frequent monitoring of serum transaminases and bilirubin if also taking valproate or in patients who have elevated liver enzymes at baseline (see Dosing Considerations)",
                        "Discontinue with transaminase levels >3 x ULN and bilirubin levels >2 x ULN",
                        "Without bilirubin elevation",
                        "Evaluate prolonged serum transaminases elevations for other possible causes; consider dosage adjustment of any coadministered medication that is known to affect liver (eg, valproate and clobazam)",
                        "Discontinue treatment with sustained transaminase elevations of >5 x ULN"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Coadministration with other CNS depressants, including alcohol, may increase risk of sedation and somnolence",
                        "Effect of other drugs on cannabidiol",
                        "Moderate or strong CYP3A4 or CYP2C19 inhibitors: Consider cannabidiol dose reduction",
                        "Strong CYP3A4 or CYP2C19 inducers: Consider cannabidiol dose increase",
                        "Effect of cannabidiol on other drugs",
                        "UGT1A9, UGT2B7, CYP2C8, CYP2C9, and CYP2C19 substrates: Consider dose reduction of substrates",
                        "Sensitive CYP2C19 substrates include diazepam and clobazam; coadministration of cannabidiol with clobazam produces a 3-fold increase in plasma concentrations of N-desmethylclobazam, the active metabolite of clobazam",
                        "Coadministration of cannabidiol and valproate increases the incidence of liver enzyme elevations; discontinuation or reduction of cannabidiol and/or concomitant valproate should be considered",
                        "CYP1A2 and CYP2B6 substrates may also require dose adjustment",
                        "No dedicated drug-drug interaction studies have been conducted with mTOR inhibitors (eg, everolimus) or calcineurin inhibitors (eg, tacrolimus); reports in literature suggest cannabidiol administration resulted in increased serum levels of everolimus, sirolimus, or tacrolimus; consider a reduction in dosage of everolimus, sirolimus, or tacrolimus, if adverse reactions known to occur with those medications are experienced when co-administered with cannabidiol"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mavacamten",
            "description": {
                "common": "cannabidiol will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "cannabidiol will increase the level or effect of tucatinib by  Other (see comment). Avoid or Use Alternate Drug. Coadministration of tucatinib (a CYP2C8 substrate) with a strong or moderate CYP2C8 inhibitors increases tucatinib plasma concentrations and risk of toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ambrisentan",
            "description": {
                "common": "cannabidiol will increase the level or effect of ambrisentan by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "cannabidiol will increase the level or effect of apalutamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bicalutamide",
            "description": {
                "common": "bicalutamide will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bortezomib",
            "description": {
                "common": "bortezomib will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "cannabidiol will increase the level or effect of bosentan by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "cannabidiol, bupropion. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "cannabidiol will increase the level or effect of carisoprodol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "cannabidiol will increase the level or effect of carvedilol by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "cannabidiol will increase the level or effect of celecoxib by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "cannabidiol will increase the level or effect of chlorpropamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "cannabidiol will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "cannabidiol will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "cannabidiol will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clotrimazole",
            "description": {
                "common": "clotrimazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "cannabidiol, conjugated estrogens. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "cannabidiol, conjugated estrogens, vaginal. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cannabidiol, cyclobenzaprine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cannabidiol, cyclophosphamide. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "cannabidiol, dacarbazine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "cannabidiol will increase the level or effect of dapsone by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasabuvir",
            "description": {
                "common": "cannabidiol will increase the level or effect of dasabuvir by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "dexlansoprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "cannabidiol will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "cannabidiol will increase the level or effect of diazepam intranasal by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Strong or moderate CYP2C19 inhibitors may decrease rate of diazepam elimination, thereby increasing adverse reactions to diazepam."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "cannabidiol will increase the level or effect of diclofenac by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "cannabidiol will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Therapeutic drug monitoring and dose reduction of P-gp substrates should be considered when given orally and concurrently with cannabidiol"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor increased cannabidol effects and toxicities if coadministered with moderate CYP3A4 inhibitors. Reduce cannabidiol dose if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "cannabidiol increases toxicity of divalproex sodium by unspecified interaction mechanism. Use Caution/Monitor. associated with increased risk of ALT and/or AST elevation; manageable by dose reduction or, in more severe cases, by discontinuation of one or both drugs; monitor liver function, including serum transaminase and total bilirubin levels, during concomitant treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin cream",
            "description": {
                "common": "cannabidiol, doxepin cream. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "cannabidiol will increase the level or effect of dronabinol by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "cannabidiol, duloxetine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "cannabidiol will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, cannabidiol.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "cannabidiol, estradiol. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "cannabidiol, estrogens conjugated synthetic. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "cannabidiol will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Therapeutic drug monitoring and dose reduction of P-gp substrates should be considered when given orally and concurrently with cannabidiol"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "cannabidiol will increase the level or effect of fenofibrate by  Other (see comment). Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit UGT1A9 activity. Consider reducing the dose when concomitantly using UGT1A9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "cannabidiol will increase the level or effect of flibanserin by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flutamide",
            "description": {
                "common": "cannabidiol, flutamide. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "cannabidiol will increase the level or effect of fluvastatin by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "fostamatinib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "cannabidiol will increase the level or effect of glimepiride by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "cannabidiol will increase the level or effect of glipizide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "cannabidiol will increase the level or effect of glyburide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "cannabidiol will increase the level or effect of ifosfamide by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "cannabidiol will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan",
            "description": {
                "common": "cannabidiol, irinotecan. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "cannabidiol will increase the level or effect of isotretinoin by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "cannabidiol will increase the level or effect of ketamine by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "cannabidiol will increase the level or effect of lacosamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "cannabidiol will increase the level or effect of lamotrigine by  Other (see comment). Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit UGT2B7 activity. Consider reducing the dose when concomitantly using UGT2B7 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "lansoprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lesinurad",
            "description": {
                "common": "cannabidiol will increase the level or effect of lesinurad by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lidocaine",
            "description": {
                "common": "cannabidiol, lidocaine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loratadine",
            "description": {
                "common": "loratadine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "cannabidiol will increase the level or effect of lorazepam by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit UGT2B7 activity. Consider reducing the dose when concomitantly using UGT2B7 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "cannabidiol will increase the level or effect of losartan by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "cannabidiol will decrease the level or effect of mestranol by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "cannabidiol, metaxalone. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "cannabidiol will increase the level or effect of methadone by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methsuximide",
            "description": {
                "common": "cannabidiol will increase the level or effect of methsuximide by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate transdermal",
            "description": {
                "common": "methylphenidate transdermal will increase the level or effect of cannabidiol by  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "cannabidiol, mexiletine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miconazole oral",
            "description": {
                "common": "miconazole oral will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "cannabidiol, mirtazapine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "montelukast",
            "description": {
                "common": "cannabidiol will increase the level or effect of montelukast by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "cannabidiol will increase the level or effect of morphine by  Other (see comment). Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit UGT2B7 activity. Consider reducing the dose when concomitantly using UGT2B7 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "cannabidiol will increase the level or effect of nateglinide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "cannabidiol, olanzapine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "cannabidiol will increase the level or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "cannabidiol will increase the level or effect of ospemifene by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "cannabidiol will increase the level or effect of paclitaxel by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "cannabidiol will increase the level or effect of paclitaxel protein bound by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "pantoprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "cannabidiol will increase the level or effect of pentamidine by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "cannabidiol, pimozide. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "cannabidiol will increase the level or effect of pioglitazone by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirfenidone",
            "description": {
                "common": "cannabidiol, pirfenidone. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "cannabidiol, pomalidomide. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "cannabidiol will increase the level or effect of progesterone intravaginal gel by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "cannabidiol will increase the level or effect of progesterone micronized by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "cannabidiol, propranolol. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "rabeprazole will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramelteon",
            "description": {
                "common": "cannabidiol, ramelteon. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rasagiline",
            "description": {
                "common": "cannabidiol, rasagiline. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "cannabidiol will increase the level or effect of repaglinide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "riluzole",
            "description": {
                "common": "cannabidiol, riluzole. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "riociguat",
            "description": {
                "common": "cannabidiol will increase the level or effect of riociguat by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "cannabidiol, ropinirole. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "cannabidiol, ropivacaine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "cannabidiol will increase the level or effect of rosiglitazone by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "schisandra",
            "description": {
                "common": "schisandra will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "cannabidiol, selegiline. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selexipag",
            "description": {
                "common": "cannabidiol will increase the level or effect of selexipag by  decreasing metabolism. Modify Therapy/Monitor Closely. Reduce selexipag dose to once daily if coadministered with moderate CYP2C8 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "cannabidiol will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Therapeutic drug monitoring and dose reduction of P-gp substrates should be considered when given orally and concurrently with cannabidiol"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sparsentan",
            "description": {
                "common": "sparsentan will decrease the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C19 inducer) decreases exposure of CYP2C19 substrates and reduces efficacy related to these substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "cannabidiol will increase the level or effect of stiripentol by  unknown mechanism. Use Caution/Monitor. Monitor for stiripentol adverse drug effects"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "cannabidiol will increase the level or effect of sulfadiazine by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "cannabidiol will increase the level or effect of sulfisoxazole by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "cannabidiol will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Therapeutic drug monitoring and dose reduction of P-gp substrates should be considered when given orally and concurrently with cannabidiol"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "cannabidiol will increase the level or effect of tamoxifen by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tasimelteon",
            "description": {
                "common": "cannabidiol, tasimelteon. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "cannabidiol, theophylline. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "cannabidiol, thiothixene. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "ticlopidine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tizanidine",
            "description": {
                "common": "cannabidiol, tizanidine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "cannabidiol will increase the level or effect of tofacitinib by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "cannabidiol will increase the level or effect of tolbutamide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "cannabidiol will increase the level or effect of torsemide by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine will increase the level or effect of cannabidiol by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP2C19 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "treprostinil",
            "description": {
                "common": "cannabidiol will increase the level or effect of treprostinil by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tretinoin",
            "description": {
                "common": "cannabidiol will increase the level or effect of tretinoin by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "cannabidiol, trifluoperazine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "cannabidiol will increase the level or effect of trimethoprim by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "cannabidiol will increase the level or effect of trimipramine by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "velpatasvir",
            "description": {
                "common": "cannabidiol, velpatasvir. affecting hepatic enzyme CYP2B6 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP2B6 induction and inhibition with the coadministration of CYP2B6 substrates and cannabidiol, consider reducing dosage adjustment of CYP2B6 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voxilaprevir",
            "description": {
                "common": "cannabidiol, voxilaprevir. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "cannabidiol will increase the level or effect of zafirlukast by  decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially  inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infections",
            "percent": "40-41"
        },
        {
            "name": "all",
            "percent": "23-25"
        },
        {
            "name": "Somnolence",
            "percent": "21-25"
        },
        {
            "name": "Infection",
            "percent": "16-22"
        },
        {
            "name": "other",
            "percent": "9-20"
        },
        {
            "name": "Decreased appetite",
            "percent": "8-16"
        },
        {
            "name": "Diarrhea",
            "percent": "7-13"
        },
        {
            "name": "Transaminases elevated",
            "percent": "11-12"
        },
        {
            "name": "Rash",
            "percent": "7-11"
        },
        {
            "name": "Fatigue",
            "percent": "5-11"
        },
        {
            "name": "malaise",
            "percent": "31"
        },
        {
            "name": "asthenia",
            "percent": "25"
        },
        {
            "name": "Infection",
            "percent": "20"
        },
        {
            "name": "viral",
            "percent": "19"
        },
        {
            "name": "Insomnia",
            "percent": "17"
        },
        {
            "name": "Diarrhea",
            "percent": "13"
        },
        {
            "name": "Elevated transaminases",
            "percent": "5-9"
        },
        {
            "name": "Decreased appetite",
            "percent": "5-8"
        },
        {
            "name": "Pyrexia",
            "percent": "3-6"
        },
        {
            "name": "Vomiting",
            "percent": "3-5"
        },
        {
            "name": "Somnolence",
            "percent": "3-5"
        },
        {
            "name": "Irritability",
            "percent": "4"
        },
        {
            "name": "agitation",
            "percent": "3"
        },
        {
            "name": "Pneumonia",
            "percent": "1-3"
        },
        {
            "name": "Sedation",
            "percent": "9"
        },
        {
            "name": "Anger",
            "percent": "9"
        },
        {
            "name": "aggression",
            "percent": "8"
        },
        {
            "name": "Decreased weight",
            "percent": "8"
        },
        {
            "name": "Gastroenteritis",
            "percent": "8"
        },
        {
            "name": "Hypoxia",
            "percent": "7"
        },
        {
            "name": "respiratory failure",
            "percent": "7"
        },
        {
            "name": "Infection",
            "percent": "5"
        },
        {
            "name": "fungal",
            "percent": "5"
        },
        {
            "name": "Gait disturbance",
            "percent": "5"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Gastroenteritis",
            "percent": "4"
        },
        {
            "name": "Ear infection",
            "percent": "4"
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Decreased weight",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Decreased platelet count",
            "percent": null
        },
        {
            "name": "Increased eosinophil count",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "Urinary tract infection",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Rhinorrhea",
            "percent": null
        }
    ]
}